Top Tweets for #mTap
I am a little late but here nonetheless! :P How about a halloween #MTAP #MyTimeAtPortia stream??? --> https://t.co/YZD1l3WIfZ
"My lady" 🧡💙
Gust x Evelyn
-------------
[My Time At Portia | OC | Builder | Gust | Evelyn Addams | EveGust | MTAP | XxReiReixX]
#mytimeatportia #mtap #OC
![XxReiReixX_arts's tweet photo. "My lady" 🧡💙
Gust x Evelyn
-------------
[My Time At Portia | OC | Builder | Gust | Evelyn Addams | EveGust | MTAP | XxReiReixX]
#mytimeatportia #mtap #OC https://t.co/ma3FHxHdMV](https://pbs.twimg.com/media/HSxkfXYWwAAeDzC.jpg)
Remake! 🧡💙
Chaged expressions, he looks so cute! 😂
-------------
[My Time At Portia | OC | Builder | Gust | Evelyn Addams | EveGust | MTAP | XxReiReixX]
#mytimeatportia #mtap #OC
![XxReiReixX_arts's tweet photo. Remake! 🧡💙
Chaged expressions, he looks so cute! 😂
-------------
[My Time At Portia | OC | Builder | Gust | Evelyn Addams | EveGust | MTAP | XxReiReixX]
#mytimeatportia #mtap #OC https://t.co/eiUX2CmHdH](https://pbs.twimg.com/media/HSXuBDsXcAA9w6I.jpg)
✏️ Old vs new! Gust x Evelyn #wip
I've never finished this pic, and now I redid it!
I think i looks better!
#mytimeatportia #mtap
I'm a tiny bit late but I could finally load our new dishwasher haha! #MTAP #MyTimeAtPortia #letsplay #live --> https://t.co/2UPASZJOce
OMG KIT IS DOING A STREAM!? (Thank goodness!) #MTAP #MyTimeAtPortia #letsplay #live --> https://t.co/cZKted424S
🧬Exciting early clinical signal in #MTAP-deleted, #KRAS-mutant #PDAC:
#Vopimetostat (PRMT5 inhibitor) + #daraxonrasib (RAS(ON) inhibitor) showed strong early Phase 1/2 activity in metastatic pancreatic cancer: 92% ORR (11/12 patients)
Early days, but promising for a historically hard-to-treat cancer type.
🔬MedChemExpress supports oncology research and drug discovery, enabling studies of key targets and emerging cancer pathways; for research use only, not for use in patients.
Vopimetostat 👉 https://t.co/ihm5Y5mXoc
Daraxonrasib 👉 https://t.co/ub6RdmJODU
🧬Molecule of the Moment | #vopimetostat + #daraxonrasib
@TangoTxOncology reported encouraging early Phase 1/2 data for vopimetostat (#PRMT5 inhibitor) in combination with Revolution Medicines’ RAS(ON) inhibitor in #MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma (#PDAC).
📊Key signals:
• 92% ORR (11/12 patients)
• 100% DCR
• ~90% 6-month PFS
In a tumor type long defined by therapeutic resistance, these results suggest true combination synergy rather than incremental benefit. Mechanistic rationale is converging:
• #RAS(ON) inhibition → dampens oncogenic signaling
• PRMT5 inhibition (MTAP-del context) → exploits synthetic lethality/metabolic vulnerability
• Together → collapse of both signaling + survival buffering
⚠️Still early: small cohorts, with key questions remaining around durability, resistance, and tolerability.
The outcome goes beyond tumor shrinkage—hinting at early durability signals driven by combination biology. If validated, MTAP-del + KRAS-mutant PDAC may become a case where tumor genotype defines a combination backbone, not just drug eligibility.
Overall, the broader direction is becoming clearer: from single-node targeting → to coordinated pathway suppression in genomically defined tumors.
🔬MedChemExpress supports oncology research and drug discovery, enabling studies of key targets and emerging cancer pathways; for research use only, not for use in patients.
Vopimetostat 👉 https://t.co/hYnMVMe3aP
Daraxonrasib 👉 https://t.co/or24dj5iUH
#KRAS #PrecisionOncology #PancreaticCancer
🧬Molecule of the Moment | #vopimetostat + #daraxonrasib
@TangoTxOncology reported encouraging early Phase 1/2 data for vopimetostat (#PRMT5 inhibitor) in combination with Revolution Medicines’ RAS(ON) inhibitor in #MTAP-deleted, RAS-mutant metastatic pancreatic ductal adenocarcinoma (#PDAC).
📊Key signals:
• 92% ORR (11/12 patients)
• 100% DCR
• ~90% 6-month PFS
In a tumor type long defined by therapeutic resistance, these results suggest true combination synergy rather than incremental benefit. Mechanistic rationale is converging:
• #RAS(ON) inhibition → dampens oncogenic signaling
• PRMT5 inhibition (MTAP-del context) → exploits synthetic lethality/metabolic vulnerability
• Together → collapse of both signaling + survival buffering
⚠️Still early: small cohorts, with key questions remaining around durability, resistance, and tolerability.
The outcome goes beyond tumor shrinkage—hinting at early durability signals driven by combination biology. If validated, MTAP-del + KRAS-mutant PDAC may become a case where tumor genotype defines a combination backbone, not just drug eligibility.
Overall, the broader direction is becoming clearer: from single-node targeting → to coordinated pathway suppression in genomically defined tumors.
🔬MedChemExpress supports oncology research and drug discovery, enabling studies of key targets and emerging cancer pathways; for research use only, not for use in patients.
Vopimetostat 👉 https://t.co/hYnMVMe3aP
Daraxonrasib 👉 https://t.co/or24dj5iUH
#KRAS #PrecisionOncology #PancreaticCancer
🤯 Outstanding results for #MTAP #KRAS altered pancreatic cancer
✅ ORR 92%
✅ DCR 100%
$TNGX @RevMedicines
@OncoAlert
Last year, we reported that KRAS+PRMT5 is synergistic in MTAP-null PDAC (https://t.co/mIc6hkbMpL). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR.
RAS inhibitors are the present, but combinations are the future!!
$TNGX $RVMD
Want to know more about how KRAS & MTAP 🧬 alterations converge in PDAC including tumor microenvironment features? You can check now at @CCR_AACR! @UTMDAnderson @AhnertJord67866 @DavidHongMD @DanZhaoMD @DrShubhamPant @BostonGeneCorp #pancreaticcancer #KRAS #MTAP
Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications | Clinical Cancer Research | American Association for Cancer Research https://t.co/8um8IN7ksn
Wishing a very, very happy birthday my friend and colleague, the #RET and #MTAP oncology 👑, @mihaela_aldea ! ❤️❤️❤️
May your birthday be filled with joy, love, and learning! @ASCO @IASLC #ASCO26 #LCSM #LCAM @RETpositive @TurgemanIlit
#ASCO2026 @MSKCancerCenter Advanced Fellow @OrlaFitz10 2 fantastic posters, #HER2 #RAS #BTC! Advanced Fellow Aruj Dhyani #YIA #ADC #BTC Assistant Attending @rohit_thum #MTAP #NET #BTC #PDAC. Glad to mentor, but grateful for what you teach me too!
#ASCO26 poster session with @rohit_thum, who shares his research about “Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers" with a fellow attendee. @ASCO
#ASCO26
Great update of #KRAS space
🗣️ @EileenMOReilly
📌 KRAS-Directed Therapy: A Clinical Update
🎯 KRASG12Ci
🎯 KRASG12Di/degrader
🎯 pan-RAS(ON/OFF)
👉🏽 Coming combinations with #MTAP #CDK #TEAD and more
@OncoAlert
#OncoAlertAF
Master #KRAS @DavidHongMD @UTMDAnderson
Insert catchy surprise stream info here!? #MTAP #live #MyTimeAtPortia --> https://t.co/9IoZGRYfu4
Last Seen Hashtags on Sotwe
雌堕
Seen from South Africa
Ligue1GN
Seen from United States
vazados
Seen from Canada
snapchat video*
Seen from United States
BringOakleyhome
Seen from United States
mgai
Seen from Netherlands
mallu ai
Seen from Malaysia
feargasm
Seen from United States
rritjaeterinjve
Seen from United States
反差
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.6M followers